186 related articles for article (PubMed ID: 23549954)
21. Efficacy and treatment costs of zoledronate versus pamidronate in paediatric osteoporosis.
Saraff V; Sahota J; Crabtree N; Sakka S; Shaw NJ; Högler W
Arch Dis Child; 2018 Jan; 103(1):92-94. PubMed ID: 28988216
[TBL] [Abstract][Full Text] [Related]
22. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
Vis M; Bultink IE; Dijkmans BA; Lems WF
Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
[TBL] [Abstract][Full Text] [Related]
23. Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study.
Forin V; Arabi A; Guigonis V; Filipe G; Bensman A; Roux C
Joint Bone Spine; 2005 Jul; 72(4):313-8. PubMed ID: 16038843
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
25. Treatment of symptomatic osteoporosis in children: a comparison of two pamidronate dosage regimens.
Martinez-Soto T; Pacaud D; Stephure D; Trussell R; Huang C
J Pediatr Endocrinol Metab; 2011; 24(5-6):271-4. PubMed ID: 21823522
[TBL] [Abstract][Full Text] [Related]
26. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
[TBL] [Abstract][Full Text] [Related]
27. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
28. Performance of five phalangeal QUS parameters in the evaluation of gonadal-status, age and vertebral fracture risk compared with DXA.
Albanese CV; Cepollaro C; de Terlizzi F; Brandi ML; Passariello R
Ultrasound Med Biol; 2009 Apr; 35(4):537-44. PubMed ID: 19097682
[TBL] [Abstract][Full Text] [Related]
29. Pamidronate and osteoporosis prevention in liver transplant recipients.
Pennisi P; Trombetti A; Giostra E; Mentha G; Rizzoli R; Fiore CE
Rheumatol Int; 2007 Jan; 27(3):251-6. PubMed ID: 16944154
[TBL] [Abstract][Full Text] [Related]
30. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
[TBL] [Abstract][Full Text] [Related]
31. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.
Reeves HL; Francis RM; Manas DM; Hudson M; Day CP
Liver Transpl Surg; 1998 Sep; 4(5):404-9. PubMed ID: 9724478
[TBL] [Abstract][Full Text] [Related]
32. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
[TBL] [Abstract][Full Text] [Related]
33. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
[TBL] [Abstract][Full Text] [Related]
34. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.
Plotkin H; Rauch F; Bishop NJ; Montpetit K; Ruck-Gibis J; Travers R; Glorieux FH
J Clin Endocrinol Metab; 2000 May; 85(5):1846-50. PubMed ID: 10843163
[TBL] [Abstract][Full Text] [Related]
35. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
Stokkers PC; Deley M; Van Der Spek M; Verberne HJ; Van Deventer SJ; Hommes DW
Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
[TBL] [Abstract][Full Text] [Related]
36. Intravenous pamidronate in juvenile osteoporosis.
Shaw NJ; Boivin CM; Crabtree NJ
Arch Dis Child; 2000 Aug; 83(2):143-5. PubMed ID: 10906023
[TBL] [Abstract][Full Text] [Related]
37. Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome.
Vujasinovic-Stupar N; Pejnovic N; Markovic L; Zlatanovic M
Rheumatol Int; 2012 Mar; 32(3):819-23. PubMed ID: 21327429
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of bone mineral density testing and osteoporosis management following low- and high-energy fractures.
Angthong C; Rodjanawijitkul S; Samart S; Angthong W
Acta Orthop Traumatol Turc; 2013; 47(5):318-22. PubMed ID: 24164940
[TBL] [Abstract][Full Text] [Related]
39. Phalangeal quantitative ultrasound technology and dual energy X-ray densitometry in patients with primary hyperparathyroidism: influence of sex and menopausal status.
Camozzi V; Lumachi F; Mantero F; Piccolo M; Luisetto G
Osteoporos Int; 2003 Jul; 14(7):602-8. PubMed ID: 12730752
[TBL] [Abstract][Full Text] [Related]
40. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
